Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fate TherapeuticsFATE +1.98%33 Cash Ratio is 4.72 as of Jun. 2026, which is 36% below its 10-year median of 7.43. GuruFocus rates FATE with a GF Score™ of 33/100 and a GF Value™ of $0.79 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,378 Biotechnology companies, Fate Therapeutics ranks better than 62.34% on this metric.
Fate Therapeutics has a Cash Ratio of 4.72. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Fate Therapeutics's Cash Ratio or its related term are showing as below:
FATE'
s Cash Ratio Range Over the Past 10 Years
Min: 3.18 Med: 7.43 Max: 11.77
Current: 4.72
During the past 13 years, Fate Therapeutics's highest Cash Ratio was 11.77. The lowest was 3.18. And the median was 7.43.
FATE's Cash Ratio is ranked better than 62.34% of 1378
companies
in the Biotechnology industry
Industry Median: 2.96
vs FATE: 4.72
Fate Therapeutics (NAS:FATE) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Fate Therapeutics Cash Ratio Related Terms
Fate Therapeutics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Fate Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fate Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fate Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Fate Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fate Therapeutics (FATE) has a Cash Ratio of 4.72 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Fate Therapeutics and its competitors. This is 36% below median its historical median of 7.43. Over the past decade, Fate Therapeutics' Cash Ratio has ranged from 3.18 to 11.77. According to the industry distribution chart, Fate Therapeutics ranks #519 out of 1378 companies in the Biotechnology industry, placing it in the top 37.7%.
Is Fate Therapeutics' Cash Ratio too high?
Fate Therapeutics' current Cash Ratio of 4.72 is 36% below median its 10-year median of 7.43. Over the past 10 years, this metric has ranged from a low of 3.18 to a high of 11.77. The Biotechnology industry median Cash Ratio is 2.96. Fate Therapeutics' value of 4.72 is 59.5% above this industry median. Based on the distribution chart, Fate Therapeutics ranks #519 out of 1378 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fate Therapeutics has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fate Therapeutics' Cash Ratio compare to IMRX and NWBO?
According to the Biotechnology industry distribution chart, Fate Therapeutics ranks #519 out of 1378 companies for Cash Ratio. This puts Fate Therapeutics in the upper half of its industry. The industry median Cash Ratio is 2.96. Fate Therapeutics' value of 4.72 is 59.5% above this benchmark. Historically, Fate Therapeutics' own Cash Ratio has ranged from 3.18 to 11.77 over the past decade. While the company's 10-year median is 7.43 vs. the industry median of 2.96, Fate Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fate Therapeutics's current Cash Ratio of 4.72 is 59.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Fate Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fate Therapeutics's current Cash Ratio is 4.72, which is 36% below median its own 10-year median of 7.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fate Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fate Therapeutics (FATE) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.79, compared to a current price of $2.57 — trading 224.7% above its estimated fair value. The current Cash Ratio is 4.72, which is 36% below median its 10-year median of 7.43 and 59.5% above the Biotechnology industry median of 2.96. Fate Therapeutics' overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Fate Therapeutics (FATE), the current Cash Ratio is 4.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fate Therapeutics (FATE) Overvalued in 2026?
Based on GuruFocus' analysis, Fate Therapeutics stock appears to be overvalued.
The current stock price of $2.57 is trading 224.7% above its estimated GF Value™ of $0.79.
GuruFocus considers Fate Therapeutics to be Significantly Overvalued.
Key valuation signals for FATE:
Cash Ratio: 4.72 (36% below median its 10-year median of 7.43)
GF Value™: $0.79 vs. price of $2.57 (224.7% above fair value)
Industry Position: 59.5% above the Biotechnology median (#519 of 1378)
No single metric tells the full story. See the FATE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
33GF Score
Get the complete analysis for FATE
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FATE has been successfully added to your 
